Cargando…
Optimizing the synthesis and purification of MS2 virus like particles
Introducing bacteriophage MS2 virus-like particles (VLPs) as gene and drug delivery tools increases the demand for optimizing their production and purification procedure. PEG precipitation method is used efficiently to purify VLPs, while the effects of pH and different electrolytes on the stability,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494748/ https://www.ncbi.nlm.nih.gov/pubmed/34615923 http://dx.doi.org/10.1038/s41598-021-98706-1 |
_version_ | 1784579382498557952 |
---|---|
author | Hashemi, Khadijeh Ghahramani Seno, Mohammad Mahdi Ahmadian, Mohammad Reza Malaekeh-Nikouei, Bizhan Bassami, Mohammad Reza Dehghani, Hesam Afkhami-Goli, Amir |
author_facet | Hashemi, Khadijeh Ghahramani Seno, Mohammad Mahdi Ahmadian, Mohammad Reza Malaekeh-Nikouei, Bizhan Bassami, Mohammad Reza Dehghani, Hesam Afkhami-Goli, Amir |
author_sort | Hashemi, Khadijeh |
collection | PubMed |
description | Introducing bacteriophage MS2 virus-like particles (VLPs) as gene and drug delivery tools increases the demand for optimizing their production and purification procedure. PEG precipitation method is used efficiently to purify VLPs, while the effects of pH and different electrolytes on the stability, size, and homogeneity of purified MS2 VLPs, and the encapsulated RNA sequences remained to be elucidated. In this regard, a vector, capable of producing VLP with an shRNA packed inside was prepared. The resulting VLPs in different buffers/solutions were assessed for their size, polydispersity index, and ability to protect the enclosed shRNA. We report that among Tris, HEPES, and PBS, with or without NaNO3, and also NaNO3 alone in different pH and ionic concentrations, the 100 mM NaNO3-Tris buffer with pH:8 can be used as a new and optimal MS2 VLP production buffer, capable of inhibiting the VLPs aggregation. These VLPs show a size range of 27-30 nm and suitable homogeneity with minimum 12-month stability at 4 °C. Moreover, the resulting MS2 VLPs were highly efficient and stable for at least 48 h in conditions similar to in vivo. These features of MS2 VLPs produced in the newly introduced buffer make them an appropriate candidate for therapeutic agents’ delivery. |
format | Online Article Text |
id | pubmed-8494748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-84947482021-10-07 Optimizing the synthesis and purification of MS2 virus like particles Hashemi, Khadijeh Ghahramani Seno, Mohammad Mahdi Ahmadian, Mohammad Reza Malaekeh-Nikouei, Bizhan Bassami, Mohammad Reza Dehghani, Hesam Afkhami-Goli, Amir Sci Rep Article Introducing bacteriophage MS2 virus-like particles (VLPs) as gene and drug delivery tools increases the demand for optimizing their production and purification procedure. PEG precipitation method is used efficiently to purify VLPs, while the effects of pH and different electrolytes on the stability, size, and homogeneity of purified MS2 VLPs, and the encapsulated RNA sequences remained to be elucidated. In this regard, a vector, capable of producing VLP with an shRNA packed inside was prepared. The resulting VLPs in different buffers/solutions were assessed for their size, polydispersity index, and ability to protect the enclosed shRNA. We report that among Tris, HEPES, and PBS, with or without NaNO3, and also NaNO3 alone in different pH and ionic concentrations, the 100 mM NaNO3-Tris buffer with pH:8 can be used as a new and optimal MS2 VLP production buffer, capable of inhibiting the VLPs aggregation. These VLPs show a size range of 27-30 nm and suitable homogeneity with minimum 12-month stability at 4 °C. Moreover, the resulting MS2 VLPs were highly efficient and stable for at least 48 h in conditions similar to in vivo. These features of MS2 VLPs produced in the newly introduced buffer make them an appropriate candidate for therapeutic agents’ delivery. Nature Publishing Group UK 2021-10-06 /pmc/articles/PMC8494748/ /pubmed/34615923 http://dx.doi.org/10.1038/s41598-021-98706-1 Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Hashemi, Khadijeh Ghahramani Seno, Mohammad Mahdi Ahmadian, Mohammad Reza Malaekeh-Nikouei, Bizhan Bassami, Mohammad Reza Dehghani, Hesam Afkhami-Goli, Amir Optimizing the synthesis and purification of MS2 virus like particles |
title | Optimizing the synthesis and purification of MS2 virus like particles |
title_full | Optimizing the synthesis and purification of MS2 virus like particles |
title_fullStr | Optimizing the synthesis and purification of MS2 virus like particles |
title_full_unstemmed | Optimizing the synthesis and purification of MS2 virus like particles |
title_short | Optimizing the synthesis and purification of MS2 virus like particles |
title_sort | optimizing the synthesis and purification of ms2 virus like particles |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494748/ https://www.ncbi.nlm.nih.gov/pubmed/34615923 http://dx.doi.org/10.1038/s41598-021-98706-1 |
work_keys_str_mv | AT hashemikhadijeh optimizingthesynthesisandpurificationofms2viruslikeparticles AT ghahramanisenomohammadmahdi optimizingthesynthesisandpurificationofms2viruslikeparticles AT ahmadianmohammadreza optimizingthesynthesisandpurificationofms2viruslikeparticles AT malaekehnikoueibizhan optimizingthesynthesisandpurificationofms2viruslikeparticles AT bassamimohammadreza optimizingthesynthesisandpurificationofms2viruslikeparticles AT dehghanihesam optimizingthesynthesisandpurificationofms2viruslikeparticles AT afkhamigoliamir optimizingthesynthesisandpurificationofms2viruslikeparticles |